Merck's Q2 2020 earnings call highlights strong oncology performance, particularly with KEYTRUDA, exceeding expectations.  Management expresses confidence in the recovery of vaccine sales and other segments in the second half of the year.  Guidance revisions reflect a more favorable outlook than previously anticipated.

[1]
